XXXX in @entity64 : report on a hospital-based @entity64 cohort.

@entity1 @entity410 @entity64 @entity4889 @entity16 @entity302 @entity204 @entity159
OBJECTIVE: To evaluate occurrence rate, clinical data, and prognostic factors of @entity159 ( @entity4889 ) after @entity64 . METHODS: From 1984 to 1994, 3,205 @entity1 were admitted to the Department of Neurology at our institution with first-time @entity64 . A total of 159 of these @entity1 had first-time @entity410 . Among these 159 @entity1 , cases of @entity4889 were identified and evaluated. RESULTS: @entity4889 was recognized in 31 @entity1 (19%). In 17 @entity1 , @entity4889 was the first @entity302 symptom (initial @entity4889 ), and in 4 @entity1 , @entity64 began with @entity4889 ( @entity4889 ). In the 14 remaining @entity1 , @entity4889 occurred after one or more @entity410 (s). After a mean follow-up period of 47 months, @entity16 occurred after @entity4889 in 15 @entity1 . This deterioration was permanent in two @entity1 . Fifteen @entity1 died; in five @entity1 , @entity204 was directly related to @entity4889 . Eight of the 17 @entity1 with initial @entity4889 and all 14 @entity1 with @entity4889 after one or more @entity410 (s) developed other @entity410 or @entity4889 . @entity4889 , however, was not a predictive factor for additional @entity410 (s). CONCLUSIONS: @entity159 is common among @entity1 with @entity410 . Although the immediate prognosis of @entity1 with @entity159 is poor, @entity159 as the presenting sign did not necessarily predict subsequent @entity302 .
